Chía
Chía
Chía, Cundinamarca, Colombia16 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Platform of Randomized Adaptive Clinical Trials in Critical Illness | Respiration Disorders, respiratory failure, respiratory system disorder | Recruiting | Not applicable | 2026-10-06 | NCT05440851 | |
| Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Recruiting | Phase 3 | 2026-10-01 | NCT06133972 | |
| Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) | DNA Virus Infections, Disease Attributes, Genital Diseases, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tumor Virus Infections, Urogenital Diseases, human papilloma virus infection, infectious disease, sexually transmitted disease, viral infectious disease, viral sexually transmitted disease | Active, not recruiting | Phase 3 | 2026-10-01 | NCT04199689 | |
| Secukinumab Open Label Roll-over Extension Protocol | Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, immune system disorder | Recruiting | Phase 4 | 2026-09-28 | NCT04638647 | |
| A Platform Trial for Gram Negative Bloodstream Infections | Gram-negative Bacteremia | Recruiting | Not applicable | 2026-09-04 | NCT06537609 | |
| A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Infarction, Lipid Metabolism Disorders, Necrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arteriosclerosis disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, coronary artery disorder, coronary stenosis, heart disorder, hyperlipidemia, ischemic disease, metabolic disease, myocardial infarction, myocardial ischemia, nervous system disorder, stroke disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-09-04 | NCT05739383 | |
| Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Active, not recruiting | Phase 3 | 2026-08-21 | NCT05624749 | |
| A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission | Axial Spondyloarthritis, Non-Radiographic Axial Spondyloarthritis, Sacroiliitis, Spondylarthritis, Spondylarthropathies, ankylosis, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, spondylitis, vertebral column disorder | Active, not recruiting | Phase 4 | 2026-08-21 | NCT05622708 | |
| Change in the Proportion of Correct Interpretations of Pulmonary Opacities | Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder | Active, not recruiting | Not applicable | 2026-08-04 | NCT07744555 | |
| A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) | Ossification, Heterotopic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fibrodysplasia ossificans progressiva, muscle tissue disorder, musculoskeletal system disorder, myositis disease, myositis ossificans | Active, not recruiting | Phase 3 | 2026-07-17 | NCT05394116 | |
| A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome | Sjogren syndrome, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Xerostomia, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, dry eye syndrome, eye disorder, immune system disorder, lacrimal apparatus disorder, mouth disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis, salivary gland disorder | Active, not recruiting | Phase 3 | 2026-04-01 | NCT05946941 | |
| Accuracy of the Sensory Test Using the Laryngopharyngeal Endoscopic Esthesiometer in Obstructive Sleep Apnea | Apnea, Dyssomnias, Neurologic Manifestations, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Respiration Disorders, Sensation Disorders, Sensory Disorders, Signs and Symptoms, Sleep Disorders, Intrinsic, disease, laryngeal disorder, nervous system disorder, obstructive sleep apnea syndrome, otorhinolaryngologic disease, respiratory system disorder, sleep apnea syndrome, sleep-wake disorder | Recruiting | Not applicable | 2026-01-08 | NCT03109171 | |
| Bioequivalence Study of Revolade® Eltrombopag 50 mg | Healthy; Healthy Donors | Active, not recruiting | Phase 4 | 2025-06-19 | NCT06834451 | |
| Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069) | DNA Virus Infections, Disease Attributes, Genital Diseases, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tumor Virus Infections, Urogenital Diseases, human papilloma virus infection, infectious disease, sexually transmitted disease, viral infectious disease, viral sexually transmitted disease | Active, not recruiting | Phase 3 | 2025-04-20 | NCT04708041 | |
| Bioequivalence Studies of Dasatinib 100 Mg | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell myeloma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Phase 4 | 2025-02-12 | NCT05944783 | |
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | COVID-19, Community-Acquired Infections, Community-Acquired Pneumonia, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, influenza, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Recruiting | Phase 3 | 2024-07-12 | NCT02735707 |